Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

IBEX Technologies Inc V.IBT

IBEX Technologies Inc., through its wholly owned subsidiary, IBEX Pharmaceuticals Inc., manufactures and markets enzymes for biomedical use. IBEX Pharmaceutical Inc.’s primary business is the manufacture and selling of high purity enzymes for in-vitro diagnostics and research. The Company also makes and sell osteoarthritis kits (ELISA’s) for pre-clinical research. The Company has developed a proprietary expression for the production of its enzymes in Flavobacterium heparinum. This expression system allows for producing each glycosaminoglycan (GAG) enzyme separately from other enzymes therefore achieving the highest purity using a well-defined proprietary purification scheme. The Company operates in one industry segment: the production and sale of diagnostic products.


TSXV:IBT - Post by User

Post by guarantor1on Jun 07, 2023 6:26pm
202 Views
Post# 35485393

It's Mclean Capital...Filed with Sedar, June 7, 16:12:43, ET

It's Mclean Capital...Filed with Sedar, June 7, 16:12:43, ET

As of the end of May, Mclean owns 12%

ALTERNATIVE MONTHLY REPORT

FORM 62-103F3 Required Disclosure by an Eligible Institutional Investor under Part 4, National Instrument 62-103

Item 1 1.1

1.2

Item 2 2.1

2.2

2.3

2.4

Item 3 3.1

– Security and Reporting Issuer

The designation of securities to which this report relates and the name and address of the head office of the issuer of the securities:

IBEX Technologies Inc. (the “Issuer”) Suite 100 – 5485 Pare Street Montreal, QC H4P 1P7

The name of the market in which the transaction or other occurrence that triggered the requirement to file this report took place:

TSX Venture

– Identity of Eligible Institutional Investor
The name and address of the eligible institutional investor:

McLean Capital Inc. (“McLean Capital”) 4020 Le Corbusier, suite 200
Laval, QC H7L 5R2

The date of the transaction or other occurrence that triggered the requirement to file this report:

The requirement to file this report was triggered on May 17, 2023 when McLean Capital acquired 82,500 shares of the Issuer at an average price of $0.81.

The names of any joint actors in connection with the disclosure required by this report:

Not applicable.

A statement that the eligible institutional investor is eligible to file reports under Part 4 of National Instrument 62-103 in respect of the reporting issuer’s securities:

McLean Capital is eligible to file reports under Part 4 of National Instrument 62-103 in respect of the above securities.

– Interest in Securities of the Reporting Issuer

The designation and the net increase or decrease in the number or principal amount of securities, and in the eligible institutional investor’s security holding percentage in the class of securities, since the last report filed by the eligible institutional investor

1

under Part 4 of National Instrument 62-103 or the early warning requirements:

Not applicable. This is an initial report.

  1. 3.2  The designation and number or principal amount of securities and the eligible institutional investor’s security holding percentage in the class of securities at the end of the month for which the report is made:

    As at the end of May 2023, McLean Capital had control over 2,969,800 Common Shares of the Issuer, representing a security holding percentage of approximately 12.0% on an undiluted basis, assuming 24,784,244 total issued and outstanding common shares.


<< Previous
Bullboard Posts
Next >>